The FDA has accepted an investigational new drug application for an investigational and proprietary combination therapy to treat frontotemporal dementia, according to a release from the ...
Results of study will inform Coya’s randomized, double-blinded Phase 2 trial of COYA 302 in patients with FTD Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage ...
- AVB-101 is an investigational one-time therapy designed to deliver a functional copy of the GRN gene directly to the brain, thereby potentially restoring progranulin levels and stopping disease ...
Hosted on MSN
The early signs of frontotemporal dementia
A loved one undergoing massive shifts in personality or speech can be challenging to work with. You might be wondering if it’s already a symptom of an underlying disease. Frontotemporal dementia (FTD) ...
Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...
Leuven, 14 June 2024 - Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two devastating neurodegenerative diseases. Scientists have long suspected a protein called FUS might ...
King of Prussia, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biotechnology company Alector announced today that the drug, latozinemab, failed to meet the criteria for safety and efficacy in a Phase 3 ...
Neuroscientists at Macquarie University in Australia have developed a single-dose genetic medicine that has been proven to halt the progression of both ALS and frontotemporal dementia (FTD) in mice – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback